Still, the optimism is palpable.
Those chocolates would “normally be gone in an hour,” she says.
She feels like the rug has been pulled out from under her.
“I’m so devastated that this option is going away,” she says.
The problem is, that’s a temporary fix, too.
GLP-1 drugs such as semaglutide and tirzepatide are at the center of aweight-loss drug revolution.
Recent research suggests these drugs could help treat a variety of other conditions, from sleep apnea toheavy drinking.
Some of these access issues were alleviated when the FDA put the drugs on its shortage list in 2022.
The thing about shortages is that they don’t last forever.
The party is over or at least it’s supposed to be.
Compounders aren’t eager to pack it in.
The OFA did not respond to a request for comment on this story.
Compounders have found a big revenue stream they don’t want to easily give up.
The transition period will not be seamless.
(It comes at a lower price point than the medication when delivered in an injection pen.)
This could very well become battleground territory.
GLP-1s are a golden goose no one wants to give up, and investors know it.
When I asked whether that meant they would keep compounding semaglutide, the response was vague.
The agency also warned that compounded drugs pose a higher risk to patients.
In January, Hims & Hers donated $1 million to Trump’s inauguration fund.
In the short term, this is going to be a mess.
Patients can enter the brand-name drugs, but insurance coverage and affordability remain problems.
On the flip side, this could also be a moment for a reset.
It could lead to the healthcare industry taking a better approach to GLP-1 access and care.
“There’s a lot of reasons why people go off of it.
“How do we work with insurers?
My hope would be that the manufacturers are also looking at that patient access.”
Generic versions of Ozempic and Mounjaro won’t be available until their patents expire.
It’s the result of how the American health system is set up.
Both the big guys and little guys are pushing these drugs onto consumers through ads on television and online.
But like many other people, she didn’t realize that.
“It’s always about money,” DeBenedetto said.
“Everything’s always about money, and it sucks.”
Emily Stewartis a senior correspondent at Business Insider, writing about business and the economy.